ライフサイエンスコーパス: thrombolytic therapy

1 ment elevation who have contraindications to thrombolytic therapy.

2 ul as a marker of microvascular injury after thrombolytic therapy.

3 better outcomes with primary PTCA than with thrombolytic therapy.

4 increased risk for hemorrhagic stroke after thrombolytic therapy.

5 tegies in patients who evolve NQMI following thrombolytic therapy.

6 uded 115 patients who evolved NQMI following thrombolytic therapy.

7 s who evolved non-Q-wave MI (NQMI) following thrombolytic therapy.

8 l infarction shortly after the initiation of thrombolytic therapy.

9 linical trials demonstrating the efficacy of thrombolytic therapy.

10 the suitability of acute stroke patients for thrombolytic therapy.

11 ersus control group who received appropriate thrombolytic therapy.

12 arkers would increase the appropriate use of thrombolytic therapy.

13 fusion success and increased mortality after thrombolytic therapy.

14 association between volume and mortality for thrombolytic therapy.

15 minutes and 24 hours after the beginning of thrombolytic therapy.

16 Recent reports have underscored the risks of thrombolytic therapy.

17 s been of great interest since the advent of thrombolytic therapy.

18 with time (5.7 mmol/L/h) unless halted with thrombolytic therapy.

19 = 2) of acute embolic stroke without or with thrombolytic therapy.

20 normal (TIMI 3) coronary flow in response to thrombolytic therapy.

21 m symptom onset, and no contraindications to thrombolytic therapy.

22 lcium channel blockers, digoxin, aspirin, or thrombolytic therapy.

23 y in acute coronary syndromes ineligible for thrombolytic therapy.

24 smin-associated thrombocytopenia seen during thrombolytic therapy.

25 t to permit safe selection of candidates for thrombolytic therapy.

26 ed cerebral artery than systemic intravenous thrombolytic therapy.

27 were prognostic indicators of no response to thrombolytic therapy.

28 thin 6 hours of symptoms, 197 (75%) received thrombolytic therapy.

29 ne the extent of Factor V proteolysis during thrombolytic therapy.

30 rculating leukocytes prior to treatment with thrombolytic therapy.

31 acute myocardial infarction and treated with thrombolytic therapy.

32 infarction and cardiogenic shock who receive thrombolytic therapy.

33 surgery, 419 patients (56%) did not receive thrombolytic therapy.

34 alyze the cleavages in plasma Factor V after thrombolytic therapy.

35 al coronary angioplasty (PTCA) compared with thrombolytic therapy.

36 schemic and hemorrhagic events subsequent to thrombolytic therapy.

37 had pulse loss with restoration in 35% after thrombolytic therapy.

38 with cardiogenic shock who are treated with thrombolytic therapy.

39 es resulted in complete thrombus lysis after thrombolytic therapy.

40 ours of stroke onset prior to treatment with thrombolytic therapy.

41 Only a minority of stroke patients receive thrombolytic therapy.

42 ential to optimize management and triage for thrombolytic therapy.

43 hway may have beneficial consequences during thrombolytic therapy.

44 tly lower mortality and more frequent use of thrombolytic therapy.

45 mbosis and have significant implications for thrombolytic therapy.

46 ulmonary embolism or serious bleeding during thrombolytic therapy.

47 ce of asymptomatic pulmonary embolism during thrombolytic therapy.

48 ass grafting (CABG) is frequently used after thrombolytic therapy.

49 ical stroke and to extend the time window of thrombolytic therapy.

50 ome, other than an increased use of patented thrombolytic therapy.

51 tion MI treated with primary PCI rather than thrombolytic therapy.

52 nary artery bypass graft (CABG) surgery, and thrombolytic therapy.

53 vor with a PE index higher than 60% received thrombolytic therapy.

54 usion with percutaneous coronary stenting or thrombolytic therapy.

55 arly marker of long-term clinical benefit of thrombolytic therapy.

56 yme have potential use in antithrombotic and thrombolytic therapy.

57 However, this model is not amenable to thrombolytic therapies.

58 t from anticoagulation, and less frequently, thrombolytic therapies.

59 sease (1.33); treatment approaches including thrombolytic therapy (1.39) and non-stent devices (1.64)

60 th HF, P<0.0001), and more likely to receive thrombolytic therapy (14% versus 11%; P=0.0001).

61 versus 27%, P = .001), and a shorter time to thrombolytic therapy (2.9 versus 3.2 hours, P = .0001) i

62 -3.6% to -1.4%; P < .001) and greater use of thrombolytic therapy (4.8% vs 1.7%; adjusted difference,

63 roup, 48.1% versus 58.2% (P = 0.03) received thrombolytic therapy, 40.5% versus 48.4% (P = 0.10) rece

64 roup, 47.3% versus 63.2% (P = 0.01) received thrombolytic therapy, 41.1% versus 53.6% (P = 0.04) rece

65 ospital ECG group was more likely to receive thrombolytic therapy (43% vs. 37%, p < 0.001) and to und

66 group, 59.5% versus 53.9% (P > 0.2) received thrombolytic therapy, 51.4% versus 45.3% (P > 0.2) recei

67 and 62.1% of TPI patients (P = 0.2) received thrombolytic therapy, 52.5% of controls and 53.3% of TPI

68 roup, 61.1% versus 67.6% (P = 0.03) received thrombolytic therapy, 53.2% versus 58.6% (P = 0.08) rece

69 spital mortality among patients who received thrombolytic therapy (7.0 percent for patients in the hi

70 Most patients who received thrombolytic therapy (76%, n=2939) received a fibrin-spe

71 t the bleeding complications associated with thrombolytic therapy after ischemic stroke might be coun

72 ute myocardial infarction (AMI) treated with thrombolytic therapy alone or with reduced-dose thrombol

73 mparing primary angioplasty with intravenous thrombolytic therapy among 2606 patients were included.

74 acute myocardial infarction (AMI) undergoing thrombolytic therapy, an elevated troponin level on admi

75 A total of 14,341 (37.8%) received thrombolytic therapy and 1,599 (4.2%) underwent primary

76 ies comprising 756 patients who had received thrombolytic therapy and 13 studies comprising 662 patie

77 ponse to ADP was measured in patients before thrombolytic therapy and 90 minutes and 24 hours after t

78 thrombolytic regimens (between initiation of thrombolytic therapy and actual achievement of reperfusi

79 With the advent of thrombolytic therapy and angioplasty, it has become poss

80 I, resulting in failure to meet criteria for thrombolytic therapy and as a consequence leading to ina

81 However, thrombolytic therapy and aspirin have significantly chan

82 It is widely used as a fibrinolytic agent in thrombolytic therapy and it is also used clinically as a

83 herapeutic efforts be directed less at using thrombolytic therapy and more toward treatment of events

84 mitted with clinical and ECG indications for thrombolytic therapy and no absolute contraindications.

85 We compared outcomes following thrombolytic therapy and primary angioplasty with no rep

86 aphic ST segment elevation were treated with thrombolytic therapy and randomly assigned to receive hi

87 Additional thrombolytic therapy and stent placement was needed in t

88 The equivalency of thrombolytic therapy and surgery for the treatment of su

89 for Registry patients who were managed with thrombolytic therapy and/or intra-aortic balloon counter

90 reperfusion therapy (primary angioplasty or thrombolytic therapy) and subsequent in-hospital mortali

91 d, including vascular pathologies, diabetes, thrombolytic therapy, and dysfibrinogenemia.

92 ith acute myocardial infarction treated with thrombolytic therapy, and in patients after elective cor

93 for subheadings (such as cardiogenic shock, thrombolytic therapy, and stress testing) and surveys of

94 presence or absence of contraindications to thrombolytic therapy, and time from the onset of symptom

95 rly infarct related artery patency following thrombolytic therapy, and to provide a paradigm which ma

96 ss likely to receive aspirin, beta-blockers, thrombolytic therapy, angiography, and angioplasty durin

97 Primary PTCA and thrombolytic therapy are alternative means of achieving

98 Appropriate candidates for thrombolytic therapy are not always identified in the em

99 Many eligible and ideal patients for thrombolytic therapy are not treated.

100 Patients who evolve NQMI following thrombolytic therapy are often considered to be at high

101 compared outcomes of primary angioplasty vs thrombolytic therapy as a function of institutional expe

102 y group did not meet ST-segment criteria for thrombolytic therapy as compared with the control group

103 ly reperfusion has led to the development of thrombolytic therapy as the cornerstone of current manag

104 d discusses the current agents available for thrombolytic therapy, as well as indications for their u

105 arction 9A and B trials received intravenous thrombolytic therapy, aspirin and either heparin (5,000

106 alyses were performed for patients receiving thrombolytic therapy at 516 hospitals.

107 al VA candidates were more likely to undergo thrombolytic therapy at arrival (OR [VA relative to Medi

108 Primary PTCA was better than thrombolytic therapy at reducing overall short-term deat

109 there was no systematic worsening of time to thrombolytic therapy, balloon inflation, medication use

110 linicians should not alter their approach to thrombolytic therapy based on HRT use.

111 the facilitated approach were mainly seen in thrombolytic-therapy-based regimens.

112 s in the proportion of patients treated with thrombolytic therapy between the stat and control groups

113 Despite the use of thrombolytic therapy, both early and late occurrences of

114 to reduce the complications associated with thrombolytic therapy, broaden the therapeutic window, an

115 ay permit rapid triage of patients receiving thrombolytic therapy by ruling out IRA occlusion.

116 rials is greatly needed to establish whether thrombolytic therapy can be considered standard of care

117 all available completed randomised trials of thrombolytic therapy compared with control in acute isch

118 there is a low haemorrhagic threshold after thrombolytic therapy compared with that in wild-type mic

119 onal analysis within a randomized trial of 4 thrombolytic therapies, conducted in 1081 hospitals in 1

120 stroke and total stroke rates were higher in thrombolytic-therapy-containing facilitated regimens tha

121 During this interval, the use of intravenous thrombolytic therapy declined from 34.3% to 20.8%, but t

122 ry PTCA remained better than those seen with thrombolytic therapy during long-term follow-up, and wer

123 a patient who was successfully treated with thrombolytic therapy during pulmonary embolism-induced c

124 as early enough to make it relevant to acute thrombolytic therapy, early BBB disruption as defined by

125 In-hospital administration of thrombolytic therapy, emergency angioplasty, ACE inhibit

126 air, venous repair-ligation, anticoagulation-thrombolytic therapy, fasciotomy) variables were studied

127 bly in some patients using catheter-directed thrombolytic therapy followed by balloon dilatation and/

128 ity of Food and Drug Administration-approved thrombolytic therapy for acute ischemic stroke since 199

129 ave been introduced are discussed, including thrombolytic therapy for acute ischemic stroke, induced

130 junctive unfractionated heparin (UFH) during thrombolytic therapy for acute myocardial infarction (AM

131 g glycoprotein (GP) IIb/IIIa inhibitors with thrombolytic therapy for acute myocardial infarction (AM

132 erfusion success and clinical outcomes after thrombolytic therapy for acute myocardial infarction (AM

133 transluminal coronary angioplasty (PTCA) or thrombolytic therapy for acute myocardial infarction (MI

134 Although thrombolytic therapy for acute myocardial infarction (MI

135 Survival benefit of thrombolytic therapy for acute myocardial infarction is

136 more important, intraocular hemorrhage after thrombolytic therapy for acute myocardial infarction is

137 tracerebral haemorrhage is a complication of thrombolytic therapy for acute myocardial infarction, pu

138 in patients with and without diabetes after thrombolytic therapy for acute myocardial infarction.

139 in patients at 90 min and 5 to 7 days after thrombolytic therapy for acute myocardial infarction.

140 ransluminal coronary angioplasty (PTCA) with thrombolytic therapy for acute ST-segment elevation myoc

141 ad ST segment monitoring was performed after thrombolytic therapy for AMI in 413 patients, 261 of who

142 th a poor prognosis in patients treated with thrombolytic therapy for AMI.

143 w is to provide an update on the progress of thrombolytic therapy for CRAO.

144 To determine whether thrombolytic therapy for elderly patients is associated

145 ndomized trials have analyzed the benefit of thrombolytic therapy for inferior MI in high risk versus

146 olume index (ESVI) at 90 to 180 minutes into thrombolytic therapy for MI is associated with adverse o

147 expected to rise with the increasing use of thrombolytic therapy for MI.

148 etween Hispanics and non-Hispanics receiving thrombolytic therapy for myocardial infarction (MI).

149 mall study population of patients undergoing thrombolytic therapy for myocardial infarction (n = 14)

150 tion and may explain the greater efficacy of thrombolytic therapy for myocardial infarction in cigare

151 In nationwide clinical practice, thrombolytic therapy for patients >75 years old is unlik

152 er ED evaluation had no effect on the use of thrombolytic therapy for patients presenting with AMI, a

153 herapy) has been an effective alternative to thrombolytic therapy for patients with acute myocardial

154 size and improve mortality in the setting of thrombolytic therapy for ST-elevation myocardial infarct

155 and safety and increase the time window for thrombolytic therapy for stroke with full- and half-dose

156 resent findings suggest that APC may improve thrombolytic therapy for stroke, in part, by reducing tP

157 the use of tissue plasminogen activator as a thrombolytic therapy for stroke.

158 unable to apply stockings, or they received thrombolytic therapy for the initial treatment of acute

159 Primary PTCA is more effective than thrombolytic therapy for the treatment of ST-segment ele

160 percutaneous coronary intervention (PCI) and thrombolytic therapy for treatment of acute myocardial i

161 These data suggest that thrombolytic therapy for treatment of CNS ischemic disor

162 rimary angioplasty appears to be superior to thrombolytic therapy for treatment of patients with acut

163 The role of thrombolytic therapy for venous thromboembolism remains

164 nalyzed for standard ST-segment criteria for thrombolytic therapy (>1 mm in two or more contiguous le

165 Although thrombolytic therapy has been a major advance in the tre

166 Recently, thrombolytic therapy has been suggested as a viable ther

167 ucted prosthetic valves is essential because thrombolytic therapy has emerged as an alternative to re

168 Thrombolytic therapy has rarely been used in these patie

169 Thrombolytic therapy has yet to be validated as an effec

170 lasty (direct angioplasty without antecedent thrombolytic therapy) has been an effective alternative

171 armacologic agents, used in conjunction with thrombolytic therapy, has emerged.

172 who are ineligible for standard intravenous thrombolytic therapy; however, its use is limited by the

173 cians documented why they did not administer thrombolytic therapy in 19% of the charts.

174 Recent trials of thrombolytic therapy in acute ischaemic stroke have give

175 tly increasing the time window for effective thrombolytic therapy in acute ischemic stroke.

176 ransluminal coronary angioplasty (PTCA) with thrombolytic therapy in acute myocardial infarction (AMI

177 review is to offer an overview of the use of thrombolytic therapy in acute pulmonary embolism.

178 whether coronary angioplasty is superior to thrombolytic therapy in anterior MI, there are no mortal

179 or these patients, there was no benefit from thrombolytic therapy in any clinical subgroup.

180 The benefit of intravenous thrombolytic therapy in elderly patients with myocardial

181 Physicians are less likely to use thrombolytic therapy in eligible patients with character

182 ry or rescue reperfusion strategy instead of thrombolytic therapy in inferior MI, unless thrombolytic

183 nd regimens aimed at broadening the scope of thrombolytic therapy in patients with acute arterial occ

184 Registry, we examined the outcomes of use of thrombolytic therapy in patients with ischemic stroke wh

185 The use of thrombolytic therapy in pediatrics has increased over th

186 The efficacy of thrombolytic therapy in reducing mortality from acute my

187 Although the benefit of thrombolytic therapy in reducing mortality in acute myoc

188 inical trials suggests a survival benefit of thrombolytic therapy in the elderly with STEMI, whereas

189 The strongest predictors of not receiving thrombolytic therapy included advanced age, absence of c

190 in more rapid administration of intravenous thrombolytic therapy, increasing use of primary angiopla

191 al data regarding the safety and efficacy of thrombolytic therapy, inferior vena cava filters, and em

192 The influence of race and age on thrombolytic therapy, invasive cardiac procedures and ou

193 Time to treatment with thrombolytic therapy is a critical determinant of mortal

194 Bolus thrombolytic therapy is a simplified means of administer

195 quate statistical power to determine whether thrombolytic therapy is associated with improved surviva

196 Rapid time to treatment with thrombolytic therapy is associated with lower mortality

197 lytics during resuscitation, the belief that thrombolytic therapy is ineffective once a patient has a

198 However, administration of conventional thrombolytic therapy is limited by a low efficacy of pre

199 When this occurs, thrombolytic therapy is not routinely administered.

200 Factor V cleavage in thrombolytic therapy is primarily plasmin mediated, rapi

201 Current treatment of ischaemic stroke with thrombolytic therapy is restricted to 3-4.5 h after symp

202 A major potential benefit of initial thrombolytic therapy is that limb ischemia can be manage

203 Thrombolytic therapy is the cornerstone of treatment of

204 time to treatment with direct PTCA, as with thrombolytic therapy, is a critical determinant of morta

205 ified systems, plasmin, the major product of thrombolytic therapy, is known to first activate then in

206 Recent controlled trials suggest that thrombolytic therapy may be an effective initial treatme

207 Case reports and case series suggest that thrombolytic therapy may be associated with lower risks

208 Thrombolytic therapy may be beneficial in the treatment

209 en for CRAO, emerging evidence suggests that thrombolytic therapy may be effective if administered pr

210 ning GPIIb/IIIa inhibition with reduced-dose thrombolytic therapy may improve early IRA patency witho

211 Thrombolytic therapy may not decrease hospital mortality

212 Intracoronary infusion of fibrin-specific thrombolytic therapy may provide a valuable and safe opt

213 Thrombolytic therapy may reduce the frequency of high in

214 nt elevation AMI to primary PTCA (n=3872) or thrombolytic therapy (n=3867).

215 ients receiving early IABP (< or = 6 h after thrombolytic therapy, n = 72) had in-hospital mortality

216 the latest prospective study has shown that thrombolytic therapy not only has no beneficial effect b

217 erfusion therapy, mainly owing to "patented" thrombolytic therapy (odds ratio 1.15; p = 0.016).

218 t has become evident that the intra-arterial thrombolytic therapy of acute ischemic stroke is at leas

219 ue in refining the selection of patients for thrombolytic therapy of prosthetic valve obstruction.

220 Thrombolytic therapy of PVT has an unpredictable risk of

221 components of thrombotic development and of thrombolytic therapy of rtPA observed from human ischemi

222 tion (P<0.001) between age and the effect of thrombolytic therapy on 30-day mortality rates.

223 Despite the benefit of thrombolytic therapy, on the basis of the results of cas

224 ge (59.3% [49.2%-69.2%]); reperfusion, using thrombolytic therapy or coronary angioplasty (67.2% [59.

225 re hemodynamically stable and do not require thrombolytic therapy or other interventions.

226 rin, beta-blockers, and reperfusion therapy (thrombolytic therapy or percutaneous coronary interventi

227 Deciding which patients should receive thrombolytic therapy or percutaneous transluminal corona

228 sample of older patients, those who received thrombolytic therapy or primary angioplasty had lower mo

229 upporting the efficacy of acute reperfusion (thrombolytic therapy or primary angioplasty) in the elde

230 our of initial ECG, and overall reperfusion (thrombolytic therapy or PTCA).

231 ed artery patency rates or reocclusion after thrombolytic therapy or ventricular functional response

232 At one year, both thrombolytic therapy (OR 0.84; 95% CI: 0.79 to 0.89) and

233 tion were 7.2% for angioplasty and 11.9% for thrombolytic therapy (OR, 0.58; 95% CI, 0.44-0.76; P<.00

234 r development in the field of intra-arterial thrombolytic therapy over the past year was the publicat

235 ve refined the selection criteria for use of thrombolytic therapy over the past year.

236 ale gender (p = 0.0006), PTCR within 24 h of thrombolytic therapy (p = 0.002), larger heparin doses d

237 shed studies evaluating the effectiveness of thrombolytic therapy, primary percutaneous coronary inte

238 As compared with thrombolytic therapy, primary percutaneous transluminal

239 Patients with cardiac arrest, thrombolytic therapy, prior revascularization, or missin

240 morbidity and mortality, and the efficacy of thrombolytic therapy propelled the development and matur

241 The median "door-to-drug" time among thrombolytic therapy recipients fell from 61.8 to 37.8 m

242 best subsequent management of patients after thrombolytic therapy remains unclear.

243 4.0% for stroke (P =.28) for primary PCI vs thrombolytic therapy, respectively.

244 includes aggressive wound care, debridement, thrombolytic therapy, restoration of tissue oxygenation,

245 Thrombolytic therapy results in the accelerated lysis of

246 Thrombolytic therapy sessions were performed under trans

247 Thrombolytic therapy should be considered first-line the

248 Acute thrombolytic therapy should be considered for all patien

249 We discuss the question of when thrombolytic therapy should be considered.

250 Thrombolytic therapy should be more successful in reduci

251 CONCLUSIONS Cardiac rupture following thrombolytic therapy tends to occur in older patients an

252 more patients undergo primary angioplasty or thrombolytic therapy than at centers with lower volumes.

253 t elevation myocardial infarction undergoing thrombolytic therapy, the degree of ST-segment resolutio

254 tion of patients most likely to benefit from thrombolytic therapy, the eligibility criteria were a pe

255 Among 13,328 women who received thrombolytic therapy, the rate of hemorrhagic stroke was

256 After thrombolytic therapy, there was considerable Factor V cl

257 Percentages of patients receiving thrombolytic therapy, thrombolytic therapy within 1 hour

258 that have impeded the more widespread use of thrombolytic therapy (tPA, tissue plasminogen activator)

259 enefits of primary angioplasty compared with thrombolytic therapy, transfer to an institution with an

260 Compared with thrombolytic therapy, treatment of patients with primary

261 ught to investigate the potential benefit of thrombolytic therapy (TT) and intra-aortic balloon pump

262 Thrombolytic therapy use increased from 0.7% to 1.0% (p

263 The TPI increased use of thrombolytic therapy, use of thrombolytic therapy within

264 Thrombolytic therapy using tissue plasminogen activator

265 es were randomized clinical trials comparing thrombolytic therapy vs anticoagulant therapy in pulmona

266 echocardiogram suggesting pulmonary embolus, thrombolytic therapy was administered during cardiopulmo

267 Q-wave MI was noted in 52% to 53%, and thrombolytic therapy was administered to 31% to 32% of p

268 Thrombolytic therapy was associated with a significant e

269 For patients 65 to 75 years old, thrombolytic therapy was associated with a survival bene

270 Among patients aged 76 to 86 years, thrombolytic therapy was associated with a survival disa

271 y stable with right ventricular dysfunction, thrombolytic therapy was associated with lower rates of

272 Among patients for whom thrombolytic therapy was clearly indicated, fewer patien

273 tcome of bleeding as a major complication of thrombolytic therapy was examined.

274 but less favorable than in patients in whom thrombolytic therapy was initially successful.

275 and physician factors, and co-interventions, thrombolytic therapy was not associated with a better 30

276 Thrombolytic therapies were permitted.

277 cute myocardial infarction without preceding thrombolytic therapy were included (n=1342).

278 ystolic BP <100 mm Hg) who were eligible for thrombolytic therapy were randomized to either transfer

279 of ST-segment elevation and the frequency of thrombolytic therapy were significantly lower in the sul

280 re 2 reperfusion strategies, primary PCI and thrombolytic therapy, which are both supported by clinic

281 nt of patients with acute ischemic stroke is thrombolytic therapy, which benefits only a fraction of

282 be old, and no absolute contraindications to thrombolytic therapy who were not referred for direct an

283 better outcomes than do patients who receive thrombolytic therapy with angioplasty only for specific

284 In some cases, such as the lower use of thrombolytic therapy with older age, these judgments are

285 Thrombolytic therapy with rtPA increases the risk of hem

286 mboembolism at baseline conditions and after thrombolytic therapy with streptokinase or alteplase.

287 on is, however, essential to improve current thrombolytic therapy with tissue plasminogen activator (

288 Recently, thrombolytic therapy with tissue-type plasminogen activa

289 ep venous system in 16 patients (80%) during thrombolytic therapy, with complete resolution of sympto

290 controls and 53.3% of TPI patients received thrombolytic therapy within 1 hour (P > 0.2), and 67.6%

291 of patients receiving thrombolytic therapy, thrombolytic therapy within 1 hour of initial ECG, and o

292 rapy, 41.1% versus 53.6% (P = 0.04) received thrombolytic therapy within 1 hour, and 50.7% versus 66.

293 rapy, 40.5% versus 48.4% (P = 0.10) received thrombolytic therapy within 1 hour, and 55.7% versus 65.

294 erapy, 51.4% versus 45.3% (P > 0.2) received thrombolytic therapy within 1 hour, and 67.6% versus 63.

295 rapy, 53.2% versus 58.6% (P = 0.08) received thrombolytic therapy within 1 hour, and 67.7% versus 74.

296 ncreased use of thrombolytic therapy, use of thrombolytic therapy within 1 hour, and use of overall c

297 erebral ischemia treated with intra-arterial thrombolytic therapy within 6 hours of symptom onset.

298 ere somewhat less likely than men to receive thrombolytic therapy within 60 minutes (adjusted relativ

299 has been identified as a contraindication to thrombolytic therapy without clear evidence that these p

300 and-1 chimera (rPSGL-Ig) in conjunction with thrombolytic therapy would enhance thrombolysis by preve